BMRN: 11x Forward Earnings But Can Management Execute?
BioMarin trades near 52-week lows with credible growth — but Roctavian's failure and the $4.8B Amicus deal demand patience before pulling the trigger.
At a Glance
- Current Price: ~$57 | 52W Range: $50.76–$66.28
- Market Cap: ~$10.9B | P/E (GAAP): 17.4x
- FY2025 Revenue: $3.22B (+13% YoY)
- 2026 Guidance: $3.325B–$3.425B revenue; Non-GAAP EPS $4.95–$5.15; ~40% Non-GAAP operating margin
- Forward Non-GAAP P/E: ~11x — cheap on its face for a rare-disease biopharma
- Analyst Consensus: $85–$95 price target, Strong Buy — 50–65% implied upside from current levels
Fundamentals
The revenue story is actually decent. FY2025 came in at $3.22B (+13% YoY), with Q4 alone at $875M (+17%). For 2026, BioMarin is guiding $3.325B–$3.425B — another 6–9% growth layer — targeting ~40% Non-GAAP operating margins.
At $57 with Non-GAAP EPS guidance of $4.95–$5.15, that's roughly 11x forward Non-GAAP earnings. For a rare-disease biopharma with consistent double-digit revenue growth and a 21.5% profit margin, that is cheap on its face. The gap between where it trades (~$57) and where analysts think it should trade ($85–$95) is notable and worth understanding — not just celebrating.
Technical Picture
Not pretty right now. Mixed signals — some MA buy signals on shorter timeframes but the overall read skews sell-heavy (roughly 10 sell, 4 buy, 3 neutral indicators as of mid-April). Volume hasn't confirmed any reversal attempt.
The stock is trading in the bottom third of its 52-week range. This is a fundamental thesis play, not a chart play. No technical momentum is calling you in.
- Support zone: $50–$53 (52W low flush territory)
- Resistance: $63–$66 before it sees real daylight
State of the Business — Honest Take
Two defining events shape the current picture:
1. Roctavian Is Dead — and That Matters
BioMarin spent years and serious capital building a hemophilia A gene therapy. Got FDA approval. Then couldn't penetrate the market. Tried to sell it. Couldn't find a buyer. Voluntarily withdrew it. That's not a minor setback — that's a billion-dollar bet that failed publicly. It raises real questions about management's ability to read market and payer dynamics. The credibility hit is real and the market discount reflects it.
2. The Amicus Acquisition Changes the Equation — If It Works
The $4.8B deal (expected close Q2 2026) adds Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) — established commercial enzyme replacement therapies with real revenue. The strategic logic is sound: lean into what BioMarin does well rather than swing on gene therapy again. But $4.8B is a large number. Integration risk, leverage, and dilution are all real variables that need to be watched closely.
Voxzogo Is the Core Growth Driver
26% growth to $240M in 2025, treating achondroplasia. This product is working. Competition is building and BioMarin's next-gen candidate (BMN 333) is still early stage. Any deceleration in Voxzogo growth is a direct hit to the core thesis.
Near-Term Catalyst: BMN 401
From the Inozyme acquisition, BMN 401 (targeting ENPP1 deficiency) has pivotal data expected in H1 2026. That's a live binary catalyst worth tracking — binary outcomes are risk, not just upside.
Trade Evaluation
- Setup: Rare-disease biopharma trading at ~11x forward Non-GAAP earnings near 52W lows, with 13% revenue growth, improving margins, and analyst consensus implying 50–65% upside.
- Risk: Roctavian failure earns a credibility discount; $4.8B Amicus integration risk; any Voxzogo growth deceleration collapses the thesis; macro and tariff environment adds noise.
- Size: Minimum until Amicus closes cleanly. Not a full-conviction entry.
- Invalidation: Amicus deal stumbles (regulatory or financial structure), Voxzogo growth decelerates below 15%, or BMN 401 data disappoints.
- Target: $75–$85 on a 12-month horizon if Amicus integrates smoothly and Voxzogo holds trajectory.
Verdict: Watch, Not Buy
The valuation is legitimately interesting at 11x forward Non-GAAP. But the market is pricing in execution risk — and the Roctavian failure earns that discount. Before conviction, two things need to happen:
- Amicus closes cleanly — no regulatory snags, integration guidance looks credible on the call
- Voxzogo maintains growth trajectory — any deceleration signal kills the core thesis
The setup to watch for: Amicus closes, combined revenue guidance is issued, and the stock holds $55+. That's the real entry signal. If it flushes toward $50–$52 on deal noise, that's where risk/reward gets genuinely asymmetric for a conventional equity position.
Right now: watch list, not a buy. Let the Amicus close be the trigger — not speculation on it.